90,000 Shares in Ocular Therapeutix, Inc. $OCUL Acquired by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 90,000 shares of the biopharmaceutical company’s stock, valued at approximately $762,000.

A number of other hedge funds also recently bought and sold shares of the company. Private Advisor Group LLC purchased a new stake in shares of Ocular Therapeutix in the 1st quarter valued at approximately $133,000. Peregrine Capital Management LLC boosted its position in Ocular Therapeutix by 26.2% during the first quarter. Peregrine Capital Management LLC now owns 720,462 shares of the biopharmaceutical company’s stock valued at $6,102,000 after purchasing an additional 149,359 shares during the last quarter. Summer Road LLC lifted its holdings in shares of Ocular Therapeutix by 6.9% during the 1st quarter. Summer Road LLC now owns 11,879,825 shares of the biopharmaceutical company’s stock valued at $100,622,000 after buying an additional 771,270 shares during the last quarter. Pictet Asset Management Holding SA lifted its stake in Ocular Therapeutix by 1,229.6% in the first quarter. Pictet Asset Management Holding SA now owns 362,596 shares of the biopharmaceutical company’s stock valued at $3,071,000 after acquiring an additional 335,324 shares during the last quarter. Finally, Union Bancaire Privee UBP SA lifted its stake in shares of Ocular Therapeutix by 13.6% in the 1st quarter. Union Bancaire Privee UBP SA now owns 25,000 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 3,000 shares during the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of Ocular Therapeutix stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider owned 2,597,170 shares of the company’s stock, valued at $21,296,794. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 28,999 shares of company stock valued at $237,792. Company insiders own 3.10% of the company’s stock.

Ocular Therapeutix Stock Performance

OCUL stock opened at $9.64 on Friday. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44. The business’s fifty day moving average is $9.11 and its 200-day moving average is $9.65. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. The company has a market cap of $2.11 billion, a P/E ratio of -6.60 and a beta of 0.88.

Analyst Ratings Changes

OCUL has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Tuesday, April 21st. Royal Bank Of Canada reissued an “outperform” rating and set a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Chardan Capital boosted their price target on shares of Ocular Therapeutix from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 25th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price (up from $21.00) on shares of Ocular Therapeutix in a report on Thursday, June 18th. Finally, Robert W. Baird increased their target price on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $25.11.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.